The Medical Letter on Drugs and Therapeutics
Secukinumab (Cosentyx) for Psoriasis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Secukinumab (Cosentyx – Novartis), an injectable human interleukin (IL)-17A antagonist, has been approved by the FDA for treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. It is the first IL-17 inhibitor to be approved for any indication in the US.

STANDARD TREATMENT — Psoriasis is a chronic inflammatory, immune-mediated condition associated with multiple comorbidities.1 Topical preparations, including corticosteroids and vitamin D analogs, are usually tried first for treatment of mild disease. UVB phototherapy can be used when the disease is more widespread or unresponsive to topical therapy. For patients with moderate to severe disease, systemic options include methotrexate, cyclosporine, the oral retinoid acitretin, and biologic therapy. Biologic agents approved to treat psoriasis include TNF ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Secukinumab (Cosentyx) for Psoriasis
Article code: 1465b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian